Racial and ethnic characteristics and cancer-specific survival in Primary Malignant Cardiac Tumors

Abstract

BackgroundThere is limited insight into the epidemiological characteristics and effect of race and ethnicity on Primary Malignant Cardiac Tumors (PMCTs).ObjectivesComparison of clinical characteristics and cancer-specific survival outcomes of major races in the United States from the Surveillance, Epidemiology and End-Result (SEER) registry.MethodsICD-O-3 codes were used to identify PMCTs for the years 1975 to 2015. Three major races were identified—“White”, “Black”, and “Asian/Pacific Islander”. Cancer-specific survival outcomes were compared using Kaplan-Meier analysis across and amongst races, based on tumor histology. A subgroup analysis of cancer-specific survival was performed between “Hispanics” and “non-Hispanics.”ResultsSeven hundred and twenty patients were identified−47% females and 79% White, mean age at diagnosis (47 ± 20 years). Black patients were significantly younger (39 ± 18 years) and presented more commonly with angiosarcomas (53%). Non-angiogenic sarcomas and lymphomas were the most common tumors in the White (38%) and Asian/Pacific Islander (34%) cohorts. For a median follow-up period of 50 (IQR3-86) months, cancer-specific survival (mean ± SD, in months) was worse in Blacks (9 ± 3) as compared to Whites (15 ± 1) and Asian/Pacific Islander (14 ± 1) (p-value; Black vs. White <0.001; Black vs. Asian/Pacific Islanders = 0.017, White vs. Asian/Pacific Islanders = 0.3). Subgroup analysis with 116 (16%) Hispanics (40% females; mean age of 40 ± 20 years) showed a longer mean cancer-specific survival of 16.9 ± 2.4 months as compared to 13.6 ± 1.1 months in non-Hispanics (p = 0.011).ConclusionBlack and non-Hispanic patients have poorer cancer-specific survival in PMCTs.

Reduced Risk of All-Cause, Cancer-, and Cardiovascular Disease-Related Mortality among Patients with Primary Malignant Cardiac Tumors Receiving Chemotherapy in the United States

“…Primary malignant cardiac tumors (PMCT) include sarcomas such as angiosarcomas, fibrosarcomas, synovial sarcomas, leiomyosarcomas, and rhabdomyosarcomas, as well as undifferentiated pleomorphic sarcomas, pericardial mesothelioma, and primary lymphomas [ 1 , 2 ]. Although rare, the incidence of PMCT has increased by more than 85% over the past four decades, owing to the increased availability and advancement of cardiac imaging instruments [ 3 , 4 , 5 ]. Comprising about 11% of all cardiac tumors [ 6 ], the incidence of PMCTs is reported to range from 34 to 131 per 10,000,000 persons [ 3 , 7 ].…”

Age and treatment disparities in survival of primary malignant cardiac tumors: an analysis of over 40 years and 500 patients

“…Even though many patients refuse surgery or other treatment due to their poor general condition or the presence of significant comorbidities, the available retrospective data suggest that multimodality treatment (including surgery, chemotherapy, and radiation) planned by a multidisciplinary team and patient-tailored may improve the relapse-free survival (RFS) and, in some cases, the overall survival (OS) ( 6 ). However, due to the lower incidence and the difficulty of early diagnosis of PMCTs, the data are limited and are mostly based on single center studies, multicenter studies with small sample sizes, case reports, and autopsy studies ( 7 - 11 ). Nevertheless, almost nothing is known on the mortality and survival rates of PMCTs currently, particularly in different age and treatment groups.…”